Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside - Marinus Pharma (NASDAQ:MRNS)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

RBC Capital Markets initiated coverage on Marinus Pharmaceuticals Inc (NASDAQ:MRNS) with an Outperform rating, Speculative Risk, and a price target of $23, equivalent to an upside of almost 300%.
The analyst writes that the company team has made substantial progress in revitalizing the prospects for the lead drug, oral ganaxolone (Ztalmy), with a solid initial launch in CDKL5 deficiency disorder (CDD) that could contribute to cash flows.
The drug should become a positive cash flow contributor by mid-'24 and ultimately achieve $75 million in annual sales.
Ganaxolone has the potential for the IV form to expand the status epilepticus treatment paradigm and achievable optionality in larger seizure disorders.
In Open-label Phase 2 trial, as per the analyst, IV ganaxolone showed promising seizure suppression. It says that IV ganaxolone will work in phase 3 in 2H23 and become the first new branded agent for the disease, with additional studies helping broaden its use in the long term.
Marinus expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial was expected in 2H of 2022.
Price Action: MRNS shares are up 15.74% at $6.03 on the last check Friday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!